Your new post is loading...
Click here to edit the content
Research and publish the best content.
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Already have an account: Login
Genetic Engineering in the Press by GEG
36.1K views |
+0 today
MorphoSys AG announced sept 6th that the first patient has been dosed in the safety evaluation phase of a phase 2/3 combination trial of MOR208 with bendamustine.